Resistant Hypertension: Evaluation and Treatment

Definition and Pathophysiology

Resistant hypertension is a clinical indicator rather than a distinct disease. It identifies patients whose blood pressure remains uncontrolled despite intensive antihypertensive treatment and who therefore require assessment for pseudo-resistance, secondary hypertension, treatment-related contributors, and excess cardiovascular risk.

The European definition requires failure to reduce office systolic and diastolic blood pressure to below 140 mmHg and 90 mmHg, respectively, despite:

• Appropriate lifestyle measures;

• A renin–angiotensin system blocker;

• A calcium channel blocker; and

• A thiazide or thiazide-like diuretic,

with all agents prescribed at maximum or maximally tolerated doses. The apparently uncontrolled office blood pressure must be confirmed using home blood pressure monitoring or ambulatory blood pressure monitoring.

Other guideline formulations similarly define resistant hypertension as blood pressure above goal despite three or more antihypertensive drugs from different classes at maximally tolerated doses, including a diuretic appropriate for kidney function. In patients with an estimated glomerular filtration rate below 30 mL/min/1.73 m², an adequately up-titrated loop diuretic is necessary before resistant hypertension can be defined.

The central physiological contributors include excess salt intake and salt and water retention, particularly when kidney function is impaired. Inadequate adherence to medication or dietary sodium restriction may therefore mimic pharmacological resistance or contribute directly to persistent hypertension.

Resistant hypertension is associated with a higher likelihood of secondary hypertension and with substantially greater cardiovascular risk than hypertension controlled with treatment. Reported risks of myocardial infarction, stroke, end-stage renal disease, and death may be two- to six-fold higher in affected adults.

True, apparent, and pseudo-resistant hypertension

The term resistant hypertension should be reserved for patients in whom the diagnosis has been carefully confirmed. Apparent resistant hypertension may result from:

• Inaccurate or inconsistent blood pressure measurement;

• White-coat hypertension;

• Poor adherence or persistence with prescribed therapy;

• Inadequate dosing;

• An inappropriate diuretic for kidney function;

• Excess dietary sodium and volume overload;

• Concomitant drugs or conditions that increase blood pressure; or

• An undiagnosed secondary cause of hypertension.

White-coat hypertension must be excluded with out-of-office measurements. Objective assessment of adherence may be undertaken where resources permit, using directly observed treatment or detection of prescribed drugs in blood or urine.

The terms “controlled resistant hypertension,” referring to blood pressure controlled with four or more medications, and “refractory hypertension,” referring to uncontrolled blood pressure despite five or more medications, are not included in the European guideline definition.

Clinical Presentation and Symptoms

The source material does not describe a distinctive symptom profile for resistant hypertension. In clinical practice, the condition is identified primarily through persistently elevated blood pressure despite multidrug treatment rather than through specific symptoms.

The clinical importance lies in its association with:

• Increased cardiovascular disease risk;

• Greater risk of myocardial infarction;

• Increased risk of stroke;

• Increased risk of end-stage renal disease;

• Increased mortality; and

• A higher probability of secondary hypertension.

Patients may also have comorbid features associated with a greater cardiovascular risk among those with resistant hypertension, including older age, Black ethnicity, elevated body mass index, diabetes, or chronic kidney disease.

Evaluation and Physical Examination

The diagnostic assessment should establish that hypertension is genuine, identify potentially remediable causes, assess comorbidities and cardiovascular risk, evaluate hypertension-mediated organ damage, and review lifestyle factors and treatment preferences.

History

The history should address:

• The exact antihypertensive regimen, including doses and duration;

• Whether treatment has been prescribed at maximum or maximally tolerated doses;

• Adherence and persistence with medication;

• Dietary sodium intake and adherence to dietary advice;

• Lifestyle measures;

• Kidney disease and estimated glomerular filtration rate;

• Diabetes and other conditions associated with cardiovascular risk;

• Concomitant medicines or conditions that may cause pseudo-resistance or resistance; and

• Features suggesting a secondary cause of hypertension.

Careful questioning about adherence is the initial step in evaluating possible non-adherence. Because the work-up is complex, patients with suspected resistant hypertension should generally be referred to specialized centres with appropriate expertise and resources.

Blood pressure assessment

Accurate blood pressure measurement is fundamental. The diagnosis requires confirmation outside the clinic by home blood pressure monitoring or ambulatory blood pressure monitoring. This step is essential because the white-coat effect can lead to substantial overdiagnosis of resistant hypertension.

Physical examination

The source material does not specify a dedicated physical-examination protocol for resistant hypertension. Physical examination should form part of the broader assessment of hypertension, cardiovascular risk, comorbidity, and possible secondary causes, but specific examination findings are not provided in the source material.

Diagnostics

Out-of-office blood pressure monitoring

Ambulatory or home blood pressure monitoring is required to confirm that apparently uncontrolled office blood pressure is persistent. A diagnosis should not be based solely on office measurements.

White-coat hypertension must be excluded before treatment is intensified or the patient is labelled as having resistant hypertension.

Laboratory and adherence assessment

The diagnostic work-up may include testing for prescribed antihypertensive drugs in blood or urine. Directly observed treatment is another option when available. These approaches are recommended for consideration in apparent resistant hypertension when resources permit.

Assessment for secondary hypertension and organ damage

Patients with resistant hypertension should be investigated for secondary hypertension and hypertension-mediated organ damage. The source material identifies secondary hypertension as more frequent in this setting but does not provide detailed testing protocols for individual secondary causes.

Because appropriate evaluation may require technologies unavailable in primary care, referral to a specialized hypertension centre is recommended.

Electrocardiography, imaging, and electrophysiology

The source material does not provide specific recommendations or findings for electrocardiography, cardiac imaging, vascular imaging, or electrophysiological testing in resistant hypertension.

Biomarkers and Laboratory Findings

No specific biomarker profile is provided. Laboratory assessment is relevant to:

• Estimation of kidney function, particularly when selecting the appropriate diuretic;

• Detection of hyperkalaemia risk before and during spironolactone therapy; and

• Objective confirmation of medication exposure through blood or urine drug assays when adherence is uncertain.

Spironolactone carries an increased risk of hyperkalaemia in patients with chronic kidney disease and an estimated glomerular filtration rate below 45 mL/min/m², particularly when blood potassium exceeds 4.5 mmol/L.

Treatment and Management

Management has two simultaneous objectives:

• Confirm true resistant hypertension and identify reversible contributors.

• Intensify treatment while reducing cardiovascular and renal risk.

Correcting pseudo-resistance

Before adding further medication, the following should be addressed:

• Confirm blood pressure with home or ambulatory monitoring;

• Review measurement technique;

• Establish adherence through careful questioning;

• Consider objective adherence testing if resources permit;

• Confirm that prescribed agents are at maximum or maximally tolerated doses;

• Ensure that the diuretic is appropriate for kidney function;

• Address dietary sodium excess;

• Evaluate for volume overload and impaired kidney function; and

• Investigate secondary hypertension.

Referral to a specialized centre is recommended for patients with suspected or confirmed resistant hypertension.

Lifestyle intervention

Lifestyle treatment remains part of the definition and management strategy. A four-month intervention combining diet and exercise within a cardiac rehabilitation programme produced significant reductions in clinic and ambulatory blood pressure in patients with resistant hypertension.

The source material does not provide specific dietary sodium targets, exercise prescriptions, weight-loss targets, or alcohol recommendations.

Pharmacological treatment

Once resistant hypertension has been confirmed despite a calcium channel blocker, a diuretic, and a renin–angiotensin system blocker, a fourth drug is generally required.

Spironolactone

Spironolactone is the most effective additional drug described for lowering blood pressure in resistant hypertension and should be considered when blood pressure remains uncontrolled despite first-line therapy.

Its use requires particular caution in chronic kidney disease and in patients with elevated baseline potassium:

• Hyperkalaemia risk is increased when estimated glomerular filtration rate is below 45 mL/min/m².

• Risk is also increased when blood potassium is above 4.5 mmol/L.

• Potassium-binding drugs may reduce the risk of hyperkalaemia.

The source material does not specify a spironolactone dose or a detailed monitoring schedule.

Alternatives when spironolactone is not tolerated

When spironolactone cannot be used or is not tolerated, evidence supports consideration of:

• Amiloride;

• Alpha-blockers;

• Beta-blockers; or

• Centrally acting agents such as clonidine.

The source material does not provide doses for these alternatives.

Diuretic selection and kidney function

A diuretic must be included in the regimen for resistant hypertension. In patients with substantially reduced kidney function, specifically an estimated glomerular filtration rate below 30 mL/min/1.73 m², an adequately up-titrated loop diuretic is required to establish that the hypertension is genuinely resistant.

Device-based treatment

Renal denervation and other device-based therapies may be considered in selected cases. The source material does not define patient-selection criteria, procedural protocols, comparative efficacy, or follow-up requirements for these interventions.

Guideline Recommendations

The major principles of guideline-based care are:

• Confirm uncontrolled blood pressure with ambulatory or home monitoring.

• Exclude pseudo-resistance, especially white-coat hypertension and non-adherence.

• Ensure that the treatment regimen includes a diuretic suitable for kidney function.

• Investigate secondary hypertension and associated target-organ damage.

• Refer suspected or confirmed cases to specialized centres.

• Use spironolactone as the preferred fourth-line pharmacological option when appropriate, while assessing hyperkalaemia risk.

Prognosis and Follow-up

Resistant hypertension identifies a population at high cardiovascular and renal risk. Compared with treated patients whose blood pressure is controlled, affected adults have higher risks of myocardial infarction, stroke, end-stage renal disease, and death. Reported excess risks range from two-fold to six-fold, although the source material does not provide outcome estimates for specific treatment strategies.

Follow-up should include:

• Repeated home or ambulatory blood pressure assessment;

• Review of adherence and persistence;

• Monitoring of kidney function and potassium when spironolactone is used;

• Ongoing assessment of dietary and lifestyle measures;

• Re-evaluation for secondary hypertension if blood pressure remains uncontrolled; and

• Continued surveillance for cardiovascular and renal complications.

The source material does not specify follow-up intervals, target values beyond the diagnostic threshold of below 140/90 mmHg, or a standardized monitoring schedule.